Physician profile
Ashlyn E Wallace
NPI 1104640887
$772.79
in general payments reported to CMS, 2019-2025
22 companies · $652 in 2025
The $652 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $121 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $124.17 | 2025 | Jakafi |
| Jazz Pharmaceuticals INC. | $111.71 | 2025 | |
| Springworks Therapeutics, INC. | $61.09 | 2025 | |
| Janssen Biotech, INC. | $59.02 | 2024 | Erleada, Rybrevant |
| Syndax Pharmaceuticals, INC. | $33.70 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.42 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.17 | 2025 | |
| Iovance Biotherapeutics, INC. | $30.06 | 2024 | Amtagvi |
| Pfizer INC. | $29.59 | 2025 | |
| Coherus Oncology, INC. | $27.35 | 2025 | Loqtorzi, Udenyca |
| Taiho Oncology, INC. | $26.35 | 2025 | |
| Exelixis INC. | $25.84 | 2025 | Cabometyx |
| Genzyme Corporation | $22.49 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.86 | 2025 | |
| Daiichi Sankyo INC. | $21.35 | 2025 | Injectafer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $19.90 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18.16 | 2025 | Qinlock, Romvimza |
| Sobi, INC | $18.16 | 2024 | |
| Puma Biotechnology, INC. | $15.90 | 2025 | |
| Glaxosmithkline, LLC. | $15.32 | 2025 | Ojjaara |
| Abbvie INC. | $13.64 | 2024 | |
| Adc Therapeutics America, INC. | $13.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlyn Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.